Product Name

GeMfibrozil

General description

Gemfibrozil, a Peroxisome Proliferator Receptor alpha Agonist, is a lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Synonym

2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid

Purity

≥98%(HPLC)

CAS Number

25812-30-0

Formula

C¹⁵H²²O³

Molecular Weight

250.33

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

White or Off-white solid

Solubility(25℃)

DMSO

≥40mg/mL

Ethanol

≥40mg/mL

Water

Insoluble

l  Biological Information

Biochem/Physiol   Actions

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately).

Gemfibrozil is a fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II results in an increase in high-density lipoprotein cholesterol (HDL-C).

Application

1. Cytochrome P-450 CYP2C8 Inhibitors

2. Hypolipidemic Agents

l  Packaging & Storage

Packaging

1g

Storage temp.

0-5℃

l  Precautions and Disclaimer

This   product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov